KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) gene mutations are predictive markers of non response to anti-epidermal growth factor receptor (anti-EGFR)1–3 and therefore valuable for prognosis and treatment of pancreatic cancer and colorectal cancer4,5. This evidence concerns the gene KRAS and pancreatic neoplasm.